

Application No. 09/522,727
Restriction Requirement dated August 4, 2003
Response to Office Action mailed June 3, 2003.

Amendments to the Claims:

This listing of claims will replace all prior version, and listings, of claims in the application.

Listing of Claims:

1. (PREVIOUSLY PRESENTED) A method of inhabiting a specific undesired immune associated reaction comprising tranducing a cell that can be involved in the undesired immune associated reaction with a gene encoding an antibody, wherein said antibody when expressed will bind in the cell to a target molecule involved in the undesired immune associated reaction, expressing the antibody and letting said antibody bind to said target molecule.
2. (PREVIOUSLY PRESENTED) The method of claim 1, wherein the target molecule is selected from the group consisting of MHC class I molecules, MHC class II molecules, CD28 molecules, CD40 molecules, CD20 molecules and CD43 molecules.
3. (PREVIOUSLY PRESENTED) The method of claim 1 wherein the target molecule is selected from the group consisting of components in the pathways involving MHC class I molecules, MHC class II molecules, CD28 molecules, CD40 molecules, CD1 molecules, CD20 molecules, T cell receptors and CD43 molecules.
4. (PREVIOUSLY PRESENTED) The method of claim 2, wherein the antibody comprises a single chain antibody.
5. (PREVIOUSLY PRESENTED) The method of claim 4, wherein the single chain antibody binds to an MHC I molecule.
6. (CANCELED)
7. (PREVIOUSLY PRESENTED) The method of claim 1, wherein said antibody binds to an MHC Class I component selected from the group consisting of MHC Class I α chains, β 2 microglobulin, calnexin, transporter associated with antigen processing (TAP) and tapasin.

Application No. 09/522,727
Restriction Requirement dated August 4, 2003
Response to Office Action mailed June 3, 2003.

8. (WITHDRAWN) A cell transduced by a gene encoding an antibody that binds to a target molecule, wherein said target molecule is a component of the major histocompatibility complex (MHC), having said antibody expressed, wherein said expressed antibody binds to the target molecule in the cell and inhibits said cell from being part of an undesired immune associated reaction.
9. (WITHDRAWN) The cell of claim 8, wherein said antibody binds to one of the group of MHC components selected from X chains of the MHC, β 2 microglobulin, calnexin, transporter associated with antigen processing (TAP) and tapasin.
10. (WITHDRAWN) The cell of claim 9, wherein said antibody binds to TAP.
11. (WITHDRAWN) The cell of claim 9, wherein the antibody is a single chain antibody.
12. (WITHDRAWN) A kit containing a vector containing a gene that encodes an antibody that binds to a component of the major histocompatibility complex (MHC), wherein said antibody has been adapted to remain in the cell, and instructions for its use in inhibiting undesired immune associated reactions.
13. (PREVIOUSLY PRESENTED) The method of claim 1, wherein the target molecule is an MHC class I molecule, and the undesired immune reaction is tissue rejection during transplantation.
14. (PREVIOUSLY PRESENTED) The method of claim 1, wherein the target molecule is an MHC class I molecule, and the undesired immune reaction is an autoimmune disease.

Application No. 09/522,727
Restriction Requirement dated August 4, 2003
Response to Office Action mailed June 3, 2003.

15. (PREVIOUSLY PRESENTED) The method of claim 1, wherein the target molecule is an MHC class I molecule, and the undesired immune reaction is tissue rejection during bone marrow transplantation.

16. (PREVIOUSLY PRESENTED) The method of claim 13, wherein the cell is an antigen presenting cell.

17. (PREVIOUSLY PRESENTED) The method of claim 13, wherein the cell is a B cell.